AngioDynamics (ANGO) Misses Q2 EPS by 2c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics (ANGO) PT Lowered to $34 at Canaccord Genuity
January 7, 2022 7:21 AM ESTCanaccord Genuity analyst William Plovanic lowered the price target on AngioDynamics (NASDAQ: ANGO) to $34.00 (from $37.00) while maintaining a Buy rating following results and sector multiple compression.
The analyst commented, "ANGO reported FQ2/22 revenue of $78.3M (+7.6% Y/Y), beating our $77.7M estimate and consensus projection of $77.9M despite building a significant backlog due to manufacturing and shipping delays. ANGOs bottom line missed our... More
